Wall Street analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to announce $147.63 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for Medidata Solutions’ earnings. The lowest sales estimate is $146.55 million and the highest is $150.17 million. Medidata Solutions reported sales of $126.82 million in the same quarter last year, which indicates a positive year-over-year growth rate of 16.4%. The business is expected to announce its next earnings report on Wednesday, April 25th.
On average, analysts expect that Medidata Solutions will report full year sales of $147.63 million for the current financial year, with estimates ranging from $634.08 million to $640.20 million. For the next fiscal year, analysts expect that the company will report sales of $745.16 million per share, with estimates ranging from $738.50 million to $752.40 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Thursday, February 8th. The company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $141.20 million for the quarter, compared to analysts’ expectations of $140.65 million. Medidata Solutions had a net margin of 8.14% and a return on equity of 11.59%. The firm’s revenue was up 13.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.33 EPS.
A number of brokerages recently commented on MDSO. Zacks Investment Research cut shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. Needham & Company LLC decreased their target price on shares of Medidata Solutions to $75.00 and set a “buy” rating on the stock in a research report on Friday, February 9th. Morgan Stanley decreased their target price on shares of Medidata Solutions from $86.00 to $79.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Royal Bank of Canada set a $82.00 target price on shares of Medidata Solutions and gave the stock a “hold” rating in a research report on Thursday, February 8th. Finally, BidaskClub upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $82.07.
Medidata Solutions (MDSO) opened at $67.33 on Friday. The company has a market cap of $3,895.02, a price-to-earnings ratio of 90.99, a P/E/G ratio of 3.36 and a beta of 1.58. Medidata Solutions has a 52-week low of $54.36 and a 52-week high of $85.92. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.50 and a quick ratio of 3.37.
In other Medidata Solutions news, Director Carlos Dominguez sold 9,066 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $66.85, for a total value of $606,062.10. Following the transaction, the director now owns 66,020 shares in the company, valued at $4,413,437. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Rouven Bergmann sold 2,000 shares of the business’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $65.95, for a total transaction of $131,900.00. Following the completion of the transaction, the chief financial officer now owns 89,775 shares in the company, valued at approximately $5,920,661.25. The disclosure for this sale can be found here. Insiders sold 20,066 shares of company stock worth $1,346,622 in the last 90 days. Corporate insiders own 5.80% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Medidata Solutions by 11.0% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,534 shares of the company’s stock valued at $666,000 after purchasing an additional 847 shares in the last quarter. Meadow Creek Investment Management LLC boosted its stake in shares of Medidata Solutions by 31.4% during the 4th quarter. Meadow Creek Investment Management LLC now owns 3,680 shares of the company’s stock valued at $233,000 after purchasing an additional 880 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in shares of Medidata Solutions by 8.7% during the 4th quarter. Essex Investment Management Co. LLC now owns 11,085 shares of the company’s stock valued at $702,000 after purchasing an additional 886 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Medidata Solutions by 48.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,242 shares of the company’s stock valued at $205,000 after purchasing an additional 1,056 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Medidata Solutions by 0.8% during the 4th quarter. TIAA CREF Investment Management LLC now owns 159,860 shares of the company’s stock valued at $10,130,000 after purchasing an additional 1,194 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Medidata Solutions Inc (MDSO) Expected to Announce Quarterly Sales of $147.63 Million” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2018/02/25/medidata-solutions-inc-mdso-expected-to-announce-quarterly-sales-of-147-63-million.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.